UNISOM SLEEPTABS- doxylamine succinate tablet Chattem, Inc.

Unisom SleepTabs

Unisom® SleepTabs®

Doxylamine succinate tablets Nighttime Sleep-Aid

Drug Facts

Active ingredient (in each tablet)

Doxylamine succinate 25 mg

Purpose

Nighttime sleep-aid

Uses

helps to reduce difficulty in falling asleep

Warnings

Do not use

- in children under 12 years of age
- with any other product containing doxylamine
- unless you have time for a full night's sleep

Ask a doctor before use if you have

- a breathing problem such as emphysema or chronic bronchitis
- glaucoma
- trouble urinating due to an enlarged prostate gland

Ask a doctor or pharmacist before use if you are taking

- sedative or any other sleep-aid
- tranquilizers
- any other antihistamines
- any other drugs

When using this product

- avoid alcoholic beverages
- do not drive a motor vehicle or operate machinery
- take only at bedtime

Stop use and ask a doctor if

 sleeplessness persists continuously for more than two weeks. Insomnia may be a symptom of serious underlying medical illness.

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Directions

- adults and children 12 years of age and over: take one tablet 30 minutes before going to bed; take once daily or as directed by a doctor
- children under 12 years of age: do not use

Other information

- Store at 20^o to 25^oC (68 o-77 oF)
- Keep carton. It contains important information

Inactive ingredients

anhydrous dibasic calcium phosphate, dibasic calcium phosphate dihydrate, FD&C blue no. 1 aluminum lake, magnesium stearate, microcrystalline cellulose, sodium starch glycolate

Questions or comments: 1-866-844-2798 Monday- Friday 8am-6pm EST

PRINCIPAL DISPLAY PANEL

Unisom Sleeptabs Doxylamine succinate 25 mg

Nighttime Sleep-Aid 32 Tablets



UNISOM SLEEPTABS

doxylamine succinate tablet

Product Information Product Type HUMAN OTC DRUG Item Code (Source) NDC:41167-0063 Route of Administration ORAL

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength

DOXYLAMINE SUCCINATE (UNII: V9BI9B5YI2) (DOXYLAMINE - UNII:95QB77JKPL) DOXYLAMINE SUCCINATE 25 mg

| Inactive Ingredients | | | |
|--|----------|--|--|
| Ingredient Name | Strength | | |
| ANHYDROUS DIBASIC CALCIUM PHOSPHATE (UNII: L11K75P92J) | | | |
| DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP) | | | |
| FD&C BLUE NO. 1 (UNII: H3R47K3TBD) | | | |
| ALUMINUM OXIDE (UNII: LMI26O6933) | | | |
| MAGNESIUM STEARATE (UNII: 70097M6I30) | | | |
| CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) | | | |
| SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) | | | |

| Product Characteristics | | | | | |
|-------------------------|------|--------------|-----------|--|--|
| Color | blue | Score | 2 pieces | | |
| Shape | OVAL | Size | 13mm | | |
| Flavor | | Imprint Code | Unisom;ST | | |
| Contains | | | | | |

| P | Packaging | | | | | | |
|---|----------------------|--|-------------------------|-----------------------|--|--|--|
| # | Item Code | Package Description | Marketing Start Date | Marketing End Date | | | |
| 1 | NDC:41167- 0063-5 | 1 in 1 CARTON | 01/15/2016 | | | | |
| 1 | | 16 in 1 BLISTER PACK; Type 0: Not a Combination Product | | | | | |
| 2 | NDC:41167- 0063-6 | 1 in 1 CARTON | 01/15/2016 | | | | |
| 2 | | 32 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product | | | | | |
| 3 | NDC:41167- 0063-7 | 1 in 1 CARTON | 01/15/2016 | | | | |
| 3 | | 48 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product | | | | | |
| 4 | NDC:41167- 0063-8 | 1 in 1 CARTON | 01/15/2016 | | | | |
| 4 | | 80 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product | | | | | |

Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|-----------------------|---|-------------------------|-----------------------|
| ANDA | ANDA040167 | 01/15/2016 | |
| | | | |

Labeler - Chattem, Inc. (003336013)

Revised: 4/2023 Chattem, Inc.